In a report released today, Andrew Fein from H.C. Wainwright maintained a Buy rating on Epizyme (EPZM), with a price target of $25. The company’s shares closed on Friday at $14.97, close to its 52-week high of $15.13.
Fein noted:
“Our price target of $25 is based on a probability-adjusted sum-of-parts NPV-DCF: $21 EZH2 (NHL + INI-) + $1 DOT1L (MLL-R) + $3 cash. Risks to our investment thesis and target price include: (1) failure in clinical trials; (2) failure to secure regulatory approvals; and (3) a smaller-than-anticipated commercial opportunity due to market sizing, competition, and pricing. Epizyme, Inc.”
According to TipRanks.com, Fein is a 3-star analyst with an average return of 0.7% and a 43.4% success rate. Fein covers the Healthcare sector, focusing on stocks such as Constellation Pharmaceuticals Inc, Proteostasis Therapeutics Inc, and ACADIA Pharmaceuticals Inc.
Epizyme has an analyst consensus of Strong Buy, with a price target consensus of $22.67, implying a 51.4% upside from current levels. In a report issued on June 12, Cowen & Co. also maintained a Buy rating on the stock with a $18 price target.
See today’s analyst top recommended stocks >>
The company has a one-year high of $15.13 and a one-year low of $5.14. Currently, Epizyme has an average volume of 783.7K.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Epizyme, Inc. is a clinical-stage biopharmaceutical company, which engage in the discovery, development, and commercialization of novel epigenetic medicines for cancer and other diseases. Its product pipeline is lead by, tazemetostat which targets Non-Hodgkin Lymphoma, molecularly defined solid tumors, non-small-cell lung carcinoma, molecularly targeted tumors, and ovarian cancer. It also develops pinometostat for genetically defined acute leukemia, and EZM8266 for sickle cell disease. The company was founded by Robert Horvitz and Zhang Yi on November 1, 2007 and is headquartered in Cambridge, MA.
